J Dermatolog Treat:Dermalax TM DEEP用于矫正中度至重度鼻唇沟的疗效和安全性

2021-10-19 MedSci原创 MedSci原创

随着年龄的增长,颌面部双侧鼻唇沟加深,在过去几年里,常会通过注射制剂来恢复面部容积。近日,发表于J Dermatolog Treat的一项随机试验比较了两种注射改性透明质酸钠凝胶在矫正和治疗中度和重度

随着年龄的增长,颌面部双侧鼻唇沟加深,在过去几年里,常会通过注射制剂来恢复面部容积。近日,发表于J Dermatolog Treat的一项随机试验比较了两种注射改性透明质酸钠凝胶在矫正和治疗中度和重度鼻唇沟方面的疗效和安全性。DermalaxTM DEEP (20 mg/1.0 ml, ACROSS CO., LTD),下面标记为Dermalax,和Restylane® (20 mg/1.0 ml, Q-Med, AB公司),下面标记为Restylane。

这项多中心、随机、双盲、积极对照的临床研究共纳入324名患有中度至重度鼻唇沟的受试者。将符合条件的受试者随机分配到测试组接受Dermalax注射(n = 162)或对照组接受Restylane注射(n = 162)。在注射后第2、8、16、24、36和48周,根据皱纹严重程度评分表(WSRS)和全球美学改善评分表(GAIS)评估临床疗效和安全性。

结果显示,在第24周,Dermalax组(93.75%)和Restylane组(89.44%)获得了类似的有效改善。在注射后36周和48周时发现,Dermalax在后期维持效果方面似乎比Restylane更好。试验组的平均WSRS评分的改善明显优于对照组。第24周的GAIS评分分别为1.65 VS. 1.94(P<0.001)和2.10 VS. 2.27(P=0.060)。

总之,研究结果表明,Dermalax在矫正中国受试者的中度至重度鼻唇沟方面不逊于或优于对照产品Restylane。对于不良事件、严重不良事件、实验室检查和生命体征等安全指标,Dermalax与Restylane相似,没有发生意外安全事件。简而言之,Dermalax可作为皮内填充物安全有效地用于矫正中国人的中度和重度鼻唇沟。

 

原始出处:

 

Ju Qiao, et al., The efficacy and safety of Dermalax TM DEEP in the correction of moderate to severe nasolabial folds: a multicenter, randomized, double-blind clinical study. J Dermatolog Treat. 2021 Aug;32(5):548-555. doi: 10.1080/09546634.2019.1687814. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1721095, encodeId=c15f1e210956a, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Tue May 24 09:01:17 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796283, encodeId=ec9d1e9628362, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Mon Oct 03 03:01:17 CST 2022, time=2022-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796938, encodeId=531d1e9693853, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Sep 15 10:01:17 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077094, encodeId=6a2720e709426, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2260, encryptionId=955d226045, topicName=ALA)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Tue May 31 13:01:17 CST 2022, time=2022-05-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1721095, encodeId=c15f1e210956a, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Tue May 24 09:01:17 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796283, encodeId=ec9d1e9628362, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Mon Oct 03 03:01:17 CST 2022, time=2022-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796938, encodeId=531d1e9693853, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Sep 15 10:01:17 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077094, encodeId=6a2720e709426, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2260, encryptionId=955d226045, topicName=ALA)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Tue May 31 13:01:17 CST 2022, time=2022-05-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1721095, encodeId=c15f1e210956a, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Tue May 24 09:01:17 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796283, encodeId=ec9d1e9628362, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Mon Oct 03 03:01:17 CST 2022, time=2022-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796938, encodeId=531d1e9693853, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Sep 15 10:01:17 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077094, encodeId=6a2720e709426, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2260, encryptionId=955d226045, topicName=ALA)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Tue May 31 13:01:17 CST 2022, time=2022-05-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1721095, encodeId=c15f1e210956a, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Tue May 24 09:01:17 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796283, encodeId=ec9d1e9628362, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Mon Oct 03 03:01:17 CST 2022, time=2022-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796938, encodeId=531d1e9693853, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Sep 15 10:01:17 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077094, encodeId=6a2720e709426, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2260, encryptionId=955d226045, topicName=ALA)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Tue May 31 13:01:17 CST 2022, time=2022-05-31, status=1, ipAttribution=)]

相关资讯

新冠发病另一种机制被找到!研发抑制透明质酸合成的特效药有望成为治疗新冠肺炎的新策略

复旦大学生物医学研究院的一个研究团队,发现了一类在细胞核内发挥独特激活作用的NamiRNA,创造性地提出NamiRNA-增强子-基因激活理论,这也为新冠致病新机制的研究打下基础。

Respiratory Research:透明质酸对治疗慢性肺部疾病有效

研究人员发现吸入透明质酸可改善慢性阻塞性肺疾病(COPD)严重加重患者的肺功能。透明质酸是一种由活组织分泌的糖,作为细胞的支架,也被用作化妆品的皮肤润肤霜和鼻腔喷雾,以滋润肺部呼吸道。

Acta Derm Venereol:悬浮在透明质酸中的非培养自体表皮细胞移植可有效且安全的治疗白癜风和斑秃病变

白癜风是一种皮肤色素脱失或减少,主要是由于黑素细胞的大量丧失。由于其对外貌美观的影响,白癜风会严重影响患者的生活质量,加重患者的心理负担。近日,发表于Acta Derm Venereol的一项随机研究

Eur Arch Otorhinolaryngol:透明质酸钠能否减轻过敏性鼻炎患者的鼻症状?

评估了在鼻腔皮质激素(NC)治疗中加入透明质酸(HA)或正常盐水(NSS)作为附加疗法,与单独的NC治疗相比,在改善间歇性AR儿童的生活质量和减少鼻部症状评分方面的临床效果。

J Periodontol:透明质酸对种植体周围炎的龈下微生物群的短期影响

截止目前,种植体周围的尚无有效的治疗方法。近日,一项随机对照试验评估了透明质酸(HA)凝胶处理45天时对种植体周围炎微生物组的影响,研究结果已在线发表于J Periodontol。

Int Wound J:细胞猪真皮、透明质酸和多核苷酸可有效治疗皮肤慢性溃疡(图片可能会引起不适)

慢性溃疡的修复往往由于局部组织的缺乏和不良的总体条件而受到阻碍。保守性的清创方法和先进的药物,如聚氨酯泡沫,作为主要手段。然而,愈合过程往往很慢,从而增加了感染或其他并发症的风险。既往研究报道,猪真皮